Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immunocore Holdings (IMCR – Research Report), Oncternal Therapeutics (ONCT – Research Report) and Ventyx Biosciences (VTYX – Research Report).
Immunocore Holdings (IMCR)
Robert W. Baird analyst Jack Allen maintained a Buy rating on Immunocore Holdings on November 7 and set a price target of $84.00. The company’s shares closed last Thursday at $48.87.
According to TipRanks.com, Allen is ranked 0 out of 5 stars with an average return of
Immunocore Holdings has an analyst consensus of Strong Buy, with a price target consensus of $83.00, which is a 59.6% upside from current levels. In a report issued on November 2, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock.
See the top stocks recommended by analysts >>
Oncternal Therapeutics (ONCT)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oncternal Therapeutics, with a price target of $2.00. The company’s shares closed last Thursday at $0.30, close to its 52-week low of $0.26.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Oncternal Therapeutics is a Moderate Buy with an average price target of $2.25.
Ventyx Biosciences (VTYX)
Ventyx Biosciences received a Hold rating from H.C. Wainwright analyst Emily Bodnar on November 7. The company’s shares closed last Thursday at $2.58, close to its 52-week low of $2.37.
According to TipRanks.com, Bodnar is ranked 0 out of 5 stars with an average return of
Ventyx Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $25.00, which is an 805.8% upside from current levels. In a report issued on November 7, LifeSci Capital also downgraded the stock to Hold with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IMCR:
- Immunocore reports Q3 EPS 4c, consensus (33c)
- Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
- Roku upgraded, Amazon initiated: Wall Street’s top analyst calls
- Immunocore initiated with an Overweight at Cantor Fitzgerald
- Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
